CSIMarket
 
Hutchmed china Limited  (HCM)
Other Ticker:  
 
 
Price: $18.7300 $0.01 0.053%
Day's High: $18.86 Week Perf: -6.77 %
Day's Low: $ 18.11 30 Day Perf: -1.37 %
Volume (M): 93 52 Wk High: $ 21.92
Volume (M$): $ 1,733 52 Wk Avg: $15.97
Open: $18.11 52 Wk Low: $10.68



 Market Capitalization (Millions $) 16,280
 Shares Outstanding (Millions) 869
 Employees 406
 Revenues (TTM) (Millions $) 838
 Net Income (TTM) (Millions $) 101
 Cash Flow (TTM) (Millions $) -53
 Capital Exp. (TTM) (Millions $) 33

Hutchmed China Limited
Hutchmed China Limited, commonly known as Hutchison China MediTech, is a biopharmaceutical company headquartered in Hong Kong, China. The company is primarily focused on discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and other medical conditions.

Hutchmed was established in 2000 as a subsidiary of Hutchison Whampoa Limited, a multinational conglomerate. In 2016, Hutchmed was spun off as an independent, publicly traded company listed on the Hong Kong Stock Exchange, raising approximately $100 million in the process.

The company's oncology portfolio consists of several late-stage clinical programs, including sulfatinib, a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), which is being developed for the treatment of advanced neuroendocrine tumors (NETs) and biliary tract cancer (BTC). Hutchmed also has several non-oncology programs, including a late-stage clinical program for the treatment of hyperuricemia and gout.

With a focus on precision medicine, the company aims to develop targeted therapies that can more effectively treat patients while reducing the risk of side effects. Hutchmed has established collaborations with leading academic institutions and pharmaceutical companies in China and internationally to advance its innovative drug discovery and development programs.

Hutchmed has a strong presence in China and has established a commercial infrastructure to support the launch of new products. The company currently has more than 600 employees, including over 200 scientists and researchers working in its R&D facilities in Shanghai, China.

In addition to its drug discovery and development programs, Hutchmed is committed to supporting cancer patients and their families. The company has launched several patient assistance programs in China to provide financial assistance and emotional support to cancer patients.

Overall, Hutchmed is a leading biopharma company with a strong focus on innovative drug discovery and development programs in oncology and other medical areas. The company's dedication to precision medicine and patient-centered care has made it a significant player in the rapidly growing global biopharmaceutical industry.


   Company Address: 48th Floor, Cheung Kong Center Central 0
   Company Phone Number: 2121 8200   Stock Exchange / Ticker: NASDAQ HCM
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

---'HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting' HONG KONG, SHANGHAI, China, and FLORHAM PARK, N.J., May 23, 2024 - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13), a leading biopharmaceutical company dedicated to the discovery and development of innovative oncology and immunology therapies, is poised to make a significant im...

Published Fri, May 24 2024 12:00 AM UTC

'Cutting-Edge Oncological Advances: HUTCHMED's Groundbreaking Presentations at ASCO 2024 and Significant Developments in AML and NSCLC Treatments'---'HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting' HONG KONG, SHANGHAI, China, and FLORHAM PARK, N.J., May 23, 2024 - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13), a leading biopharmaceutical company dedic...

Product Service News

HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., May 17, 2024 - HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:HCM; HKEX:13) has announced its latest groundbreaking advancements in cancer research. The company will present the highly anticipated topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, along with new and updated data related to novel investigation...

Published Fri, May 17 2024 12:00 AM UTC

HUTCHMED Presents Exciting Data on Sovleplenib Phase III Study and Hematological Malignancy Programs at EHA2024 CongressHONG KONG, SHANGHAI, and FLORHAM PARK, N.J., May 17, 2024 - HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:HCM; HKEX:13) has announced its latest groundbreaking advancements in cancer research. The company will present the highly anticipated topline and su...

Product Service News

HUTCHMED Boosts AML and Autoimmune Hemolytic Anemia Treatments with Breakthrough Drugs in China

Published Tue, May 14 2024 12:00 AM UTC

In recent announcements, HUTCHMED (China) Limited has showcased its dedication to advancing the treatment landscape for two challenging medical conditions: mutated isocitrate dehydrogenase (IDH) 1 or 2 relapsed/refractory acute myeloid leukemia (AML), and warm antibody autoimmune hemolytic anemia (wAIHA). With the initiation of the Phase III trial for HMPL-306 in AML patient...

Product Service News

Promising Advances in Savolitinib: Expanding Treatment Options for Locally Advanced or Metastatic MET Exon 14 NSCLC Patients

Published Thu, Mar 28 2024 12:00 AM UTC

In recent developments in the field of oncology, HUTCHMED, a leading biopharmaceutical company, has made a significant breakthrough with its drug Savolitinib. The National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for Savolitinib, marking an important milestone for the innovative treatment. Furthermore, at the E...

Product Service News

HUTCHMED Takes a Step Closer to Addressing Unmet Needs in Warm Antibody Autoimmune Hemolytic Anemia Through Initiation of Phase II/III Trial of Sovleplenib in China

Published Fri, Mar 22 2024 12:00 AM UTC

HUTCHMED, a leading biopharmaceutical company, has recently announced the initiation of the registration stage for the Phase II/III clinical trial of their drug sovleplenib. The trial aims to evaluate the efficacy and safety of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) in China. This marks a significant milestone in HUTCHMED's effor...






 

Hutchmed China Limited's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Hutchmed China Limited does not provide revenue guidance.

Earnings Outlook
Hutchmed china Limited does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com